Detalhe da pesquisa
1.
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.
Pharmacol Res;
199: 107040, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38128857
2.
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
Am J Physiol Endocrinol Metab;
325(5): E595-E609, 2023 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37729025
3.
Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
Diabetes Obes Metab;
25(6): 1658-1667, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36789682
4.
Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.
Cell Mol Life Sci;
79(5): 273, 2022 May 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35503137
5.
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
Pharmacol Res;
182: 106320, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35738455
6.
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study.
Pharmacol Res;
183: 106396, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35970329
7.
Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
Pharmacol Res;
183: 106374, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35908663
8.
Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Pharmacol Res;
171: 105782, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34302978
9.
Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.
Pharmacol Res;
137: 270-279, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30213563
10.
Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Pharmacol Res;
137: 219-229, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30359962
11.
Managing Patients With Nonalcoholic Fatty Liver Disease: Is It Really Only About Fibrosis?
Gastroenterology;
155(3): 926-928, 2018 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30077626
12.
AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.
Acta Diabetol;
60(9): 1257-1266, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37270748
13.
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
Front Endocrinol (Lausanne);
13: 1099451, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36743930
14.
Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes.
Diabetes;
71(8): 1800-1806, 2022 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35551366
15.
Obesity Is Strongly Associated With Low Testosterone and Reduced Penis Growth During Development.
J Clin Endocrinol Metab;
106(11): 3151-3159, 2021 10 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34283215
16.
Telemedicine and urban diabetes during COVID-19 pandemic in Milano, Italy during lock-down: epidemiological and sociodemographic picture.
Acta Diabetol;
58(7): 919-927, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33740123
17.
Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety.
Diabetes Ther;
11(1): 97-105, 2020 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31707573
18.
Hypoglycemia and hyperglycemia are risk factors for falls in the hospital population.
Acta Diabetol;
56(8): 931-938, 2019 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30929079
19.
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
Lancet Diabetes Endocrinol;
11(12): 894-895, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37996193
20.
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety.
Diabetes Ther;
9(6): 2209-2218, 2018 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30242611